Current status of carbapenem antibiotics

Current Topics in Medicinal Chemistry

Volumn 10, Issue 18, 2010, Pages 1882-1897

  El Gamal, Mohammed I ^a   Oh, Chang Hyun ^b  

^a University of Science and Technology (UST)   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

Carbapenemases; Carbapenems; Community acquired infections; Multidrug resistance; Nosocomial infections; Polymicrobial infections; lactamases; lactams

Indexed keywords

BIAPENEM; CARBAPENEM DERIVATIVE; CILASTATIN PLUS IMIPENEM; DORIPENEM; ERTAPENEM; LENAPENEM; MEROPENEM; METHYL GROUP; PANIPENEM PLUS BETAMIPRON; TEBIPENEM; TEBIPENEM PIVOXIL; THIENAMYCIN; TOMOPENEM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG ACTIVITY; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; NONHUMAN;

EID: 78649946454     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610793176639     Document Type: Article

References (185)

1. Turner, P. J. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn. Microbiol. Infect. Dis., 2008, 60, 185-192.
2. Richards, M. J.; Edwards, J. R.; Culver, D. H.; Gaynes, R. P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med., 1999, 27, 887-892.
3. Richards, M. J.; Edwards, J. R.; Culver, D. H.; Gaynes, R. P. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol., 2000, 21, 510-515.
4. Gaynes, R.; Edwards, J. R. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis., 2005, 41, 848-854.
5. Thomson, J. M.; Bonomo, R. A. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril! Curr. Opin. Microbiol., 2005, 8, 518-524.
6. Zhanel, G. G.; Wiebe, R.; Dilay, L.; Thomson, K.; Rubinstein, E.; Hoban, D. J.; Noreddin, A. M. Comparative review of the carbapenems. Drugs, 2007, 67, 1027-1052.
7. Livermore, D. M.; Neil, W. Carbepenemases: a problem in waiting? Curr. Opin. Microbiol., 2000, 3, 489-495.
8. Mody, R. M.; Erwin, D. P.; Summers, A. M.; Carrero, H. A.; Selby, E. B.; Ewell, A. J.; Moran, K. A. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann. Clin. Microbiol. Antimicrob, 2007, 6, 6.
9. Saurez, C. J.; Lolans, K.; Villegas, M. V.; Quinn, J. P. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections. Expert. Rev. Anti Infect. Ther., 2005, 3, 915-922.
10. Kattan, J. N.; Villegas, M. V.; Quinn, J. P. New developments in carbapenems. Clin. Microbiol. Infect., 2008, 14, 1102-1111.
11. Basseti, M.; Nicolini, L.; Esposito, S.; Right, E.; Viscoli, C. Current status of newer carbapenems. Curr. Med. Chem., 2009, 16, 564-575.
12. Livermore, D. M. The threat from the pink corner. Ann. Med., 2003, 35, 226-234.
13. Deshpande, L. M.; Rhomberg, P. R.; Sader, H. S.; Jones, R. N. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC program (1999-2005). Diagn. Microbiol. Infect. Dis., 2006, 56, 367-372.
14. Deshpande, L. M.; Jones, R. N.; Fritsche, T. R.; Sader, H. S. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program (2000-2004). Microb. Drug Resist., 2006, 12, 223-230.
15. Cai, J. C.; Zhou, H. W.; Chen, G. X.; Zhang, R. Detection of plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in a strain of carbapenem-resistant Enterobacter cloacae. Zhonghua Yi Xue Za Zhi, 2008, 88, 135-138.
16. Cuzon, G.; Naas, T.; Demachy, M. C.; Nordmann, P. Plasmidmediated carbapenem-hydrolyzing {beta}-lactamase KPC-2 in Klebsiella pneumoniae from Greece. Antimicrob. Agents. Chemother., 2008, 52, 796-797.
17. Gülmez, D.; Woodford, N.; Palepou, M. F.; Mushtaq, S.; Metan, G.; Yakupogullari, Y.; Kocagoz, S.; Uzun, O.; Hascelik, G.; Livermore, D. M. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int. J. Antimicrob. Agents, 2008, 31, 523-526.
18. Sanschagrin, F.; Couture, F.; Levesquw, R. C. Primary structure of OXA-3 and phylogeny of oxacillin-hydrolyzing class D betalactamases. Antimicrob. Agents Chemother., 1995, 39, 887-893.
19. Hornstein, M.; Sautjeau-Rostoker, C.; Péduzzi, J.; Vessières, A.; Hong, L. T.; Barthélémy, M.; Scavizzi, M.; Labia, R. Oxacillinhydrolyzing beta-lactamase involved in resistance to imipenem in Acinetobacter baumannii. FEMS Microbiol. Lett., 1997, 153, 333-339.
20. Jacoby, G. A.; Munoz-Price, L. S. The new beta-lactamases. N. Engl. J. Med., 2005, 352, 380-391.
21. Fish, D. N. Meropenem in the treatment of complicated skin and soft tissue infections. Ther. Clin. Risk Manag., 2006, 2, 401-415.
22. Dalhoff, A.; Janjic, N.; Echols, R. Redefining penems. Biochem. Pharmacol., 2006, 71, 1085-1095.
23. Nazarov, A. D.; Zhelaev, A. A. Non-traditional beta lactamscarbapenems, penems and monocyclic antibiotics. Antibiotiki I Khimioterapii a, 1991, 36, 42-47.
24. Birnbaum, J.; Kahan, F. J.; Kropp, H.; MacDonald, J. S. Carbapenems, a new class of beta-lactam antibiotics. Am. J. Med., 1985, 78(Suppl. 6A), 3-21.
25. Hammond, M. L. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. J. Antimicrob. Chemother., 2004, 53(Suppl. 2), ii7-ii9.
26. Taibi, P.; Mobashery, S. Mechanism of turnover of imipenem by the TEM β-lactamase revisited. J. Am. Chem. Soc., 1995, 117, 7600-7605.
27. Nukaga, M.; Bethel, C. R.; Thomson, J. M.; Hujer, A. M.; Distler, A.; Anderson, V. E.; Knox, J. R.; Bonomo, R. A. Inhibition of class A β-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J. Am. Chem. Soc., 2008, 130, 12656-12662.
28. Miyashita, K.; Massova, I.; Mobashery, S. Quantification of the extent of attenuation of the rate of turnover chemistry of the TEM-1 β-lactamase by the β-1R-hydroxyethyl group in substrates. Bioorg. Med. Chem. Lett., 1996, 6, 319-322.
29. Kahan, F. M.; Kropp, H.; Sundelof, J. G.; Birnbaum, J. Thienamycin: development of imipenem-cilastatin. J. Antimicrob. Chemother., 1983, 12 (Suppl. D), 1-35.
30. Shin, D. H.; Baker, F.; Cama, L.; Christensen, B. G. Synthetic carbapenem antibiotics. I. 1-β-Methylcarbapenem. Heterocycles, 1984, 21, 29-40.
31. Sundelof, J. G.; Hajdu, R.; Gill, C. J.; Thompson, R.; Rosen, H.; Kropp, H. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrob. Agents Chemother., 1997, 41, 1743-1748.
32. Moellering, R. C. Jr.; Eliopoulos, G. M.; Sentochnik, D. E. The carbapenems: new broad spectrum beta-lactam antibiotics. J. Antimicrob. Chemother., 1989, 24 (Suppl.), 1-7.
33. Chambers, H. F. Other β-lactam antibiotics. In Principles and Practice of Infectious Diseases; Mandell, G. L.; Bennett, J. E.; Dolin, R.; Eds.; PA: Elsevier Churchill Livingstone, Philadelphia, 2005, pp 311-317.
34. Unal, S.; Garcia-Rodriguez, J. A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. Isolated in the MYSTIC program, 2002-2004. Diagn. Microbiol. Infect. Dis., 2005, 53, 265-271.
35. Quale, J.; Bratu, S.; Gupta, J.; Landman, D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother., 2006, 50, 1633-1641.
36. Hellinger, W. C; Brewer, N. S. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo. Clin. Proc., 1999, 74, 420-434.
37. Tellado, J. M.; Wilson, S. E. Empiric treatment of nosocomial intraabdominal infections: a focus on the carbapenems. Surg. Infect., (Larchmt) 2005, 6, 329-343.
38. Livermore, D. M.; Carter, M. W.; Bagel, S.; Wiedemann, B.; Baquero, F.; Loza, E.; Endtz, H. P.; van Den Braak, N.; Fernandes, C. J.; Fernandes, L.; Frimodt-Moller, N.; Rasmussen, L. S.; Giamarellou, H.; Giamarellos-Bourboulis, E.; Jarlier, V.; Nguyen, J.; Nord, C. E.; Struelens, M. J.; Nonhoff, C.; Turnidge, J.; Bell, J.; Zbinden, R.; Pfister, S.; Mixson, L.; Shungu, D. L. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob. Agents Chemother., 2001, 45, 1860-1867.
39. John, R.; Brazier, J. S. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J. Hosp. Infect., 2005, 61, 11-14.
40. Bonfiglio, G.; Russo, G.; Nicoletti, G. Recent developments in carbapenems. Expert Opin. Investig. Drugs, 2002, 11, 529-544.
41. Shah, P. M.; Isaacs, R. D., Ertapenem, the first of a new group of carbapenems. J. Antimicrob. Chemother., 2003, 52, 538-542.
42. Lolans, K.; Quinn, J. P. PZ-601 Susceptibility against Gramnegative pathogens with known resistance mechanisms. Programs and abstracts of the American society for microbiology's 47th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007.
43. Kahan, J. S.; Kahan, F. M.; Goegelman, R.; Currie, S. A.; Jackson, M.; Stapley, E. O.; Miller, T. W.; Miller, A. K.; Hendlin, D.; Mochales, S.; Hernandez, S.; Woodruff, H. B.; Birnbaum, J. Thienamycin, a new β-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J. Antibiot., 1979, 32, 1-12.
44. Kropp, H.; Kahan, J. S.; Kahan, F. M.; Sundelof, J.; Darland, G.; and Birnbaum, J. Thienamycin, A New β-lactam Antibiotic. II. In vitro and in vivo evaluation. Presented at the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, III., Oct. 1976.
45. Schǒnberg, G. A.; Arison, B. H.; Hensens, O. D.; Hirshfield, J.; Hoogsteen, K.; Kaczka, E. A.; Rhodes, R. E.; Kahan, J. S.; Kahan, F. M.; Ratcliffe, R. W.; Walton, E.; Ruswinkle, L. J.; Morin, R. B.; Christensen, B. G. Structure and absolute configuration of thienamycin. J. Am. Chem. Soc., 1978, 106, 6491-6499.
46. Kropp, H.; Kahan, J. S.; Kahan, F. M.; Sundelof, J.; Darland, G.; Birnbaum, J. Thienamycin: in vitro and in vivo evaluation. 16th Intersci. Conf. Antimicrob. Agents Chemother. 1976, Abstr. 228.
47. Aoki, H.; Okuhara, M. Natural beta-lactam antibiotics. Annu. Rev. Microbiol. 1980, 34, 159-181.
48. Brown, A. G.; Corbett, D. F.; Eglington, A. J.; Howarth, T. T. Structures of olivanic acid derivatives MM 4550 and MM 13902; two new, fused β-lactams isolated from Streptomyces olivaceus. J. Chem. Soc. Chem. Commun., 1977, 15, 523-525.
49. Brown, A. G.; Corbett, D. F.; Eglington, A. J.; Howarth, T. T. Structures of olivanic acid derivatives MM 22380, MM 22381, MM 22382 and MM 22383; four new antibiotics isolated from Streptomyces olivaceus. J. Antibiot., 1979, 32, 961-963.
50. Nakayama, M.; Iwasaki, A.; Kimura, S.; Mizoguchi, T.; Tanabe, S.; Murakami, A.; Watanabe, I.; Okuchi, M.; Itoh, H.; Saino, Y.; Fujio, K.; Mori, T. Carpetimycins A and B, new β-lactam antibiotics. J. Antibiot., 1980, 33, 1388-1390.
51. Tanaka, K.; Shoji, J.; Terui, Y.; Tsuji, N.; Kondo, E.; Mayama, M.; Kawamura, Y.; Hattori, T.; Matsumoto, K.; Yoshida, T. Asparenomycin A, a new carbapenem antibiotic. J. Antibiot., 1981, 34, 909-911.
52. Tsuji, N.; Nagashima, K.; Kobayashi, M.; Terui, Y.; Matsumoto, K.; Kondo, E. The structures of pluracidomycins, new carbapenem antibiotics. J. Antibiot., 1982, 35, 536-540.
53. Okamura, K.; Hirata, S.; Okumura, Y.; Fukagawa, Y.; Shimauchi, Y.; Kouno, K.; Ishikura, T. PS-5, a new β-lactam antibiotic from Streptomyces. J. Antibiot., 1978, 31, 480-482.
54. Kropp, H.; Sundelof, J. G.; Hajdu, R.; Kahan, F. M. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob. Agents Chemother., 1982, 22, 62-70.
55. Kropp, H.; Sundelof, J. G.; Kahan, J. S.; Kahan, F. M.; Birnbaum, J. MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob. Agents Chemother. 1980, 17, 993-1000.
56. Leanza, W. J.; Wildonger, K. J.; Miller, T. W.; Christensen, B. G. N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics. J. Med. Chem., 1979, 22, 1435-1436.
57. Kahan, J. S.; Kahan, F. M.; Goegelman, R. T.; Stapley, E. O.; Hernandez, S. Antibiotic 924A1. Ger. Offen. 2 652-681, 1977.
58. Rodloff, A. C.; Goldstein, E. J.; Torres, A. Two decades of imipenem therapy. J. Antimicrob. Chemother., 2006, 58, 916-929.
59. Quinn, J. P.; Dudek, E. J.; DiVincenzo, C. A.; Lucks, D. A.; Lerner, S. A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis., 1986, 154, 289-294.
60. Ishii, Y.; Iwata, M.; Murakami, H.; Yamaguchi, K. Annual change of susceptibility of Pseudomonas aeruginosa isolated from lower respiratory tract or urinary tract infections against antibacterial agents. Jpn. J. Chemother., 2004, 52, 256-264.
61. Vurma-Rapp, U.; Kayser, F. H.; Hadorn, K.; Wiederkehr, F. Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy. Eur. J. Clin. Microbiol. Infect. Dis., 1990, 9, 580-587.
62. Ballestero, S.; Fernandez-Rodriguez, A.; Villaverde, R.; Escobar, H.; Perez-Diaz, J. C.; Baquero, F. Carbapenem resistance in Pseu domonas aeruginosa from cystic fibrosis patients. J. Antimicrob. Chemother., 1996, 38, 39-45.
63. Kohler, T.; Michea-Hamzehpour, M.; Epp, S. F.; Pechere, J.-C. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother., 1999, 43, 424-427.
64. Smith, G. B.; Dezeny, G. C.; Douglas, A. W. Stability and kinetics of degradation of imipenem in aqueous solution. J. Pharm. Sci., 1990, 79, 732-740.
65. Viaene, E.; Chanteux, H.; Servais, H.; Mingeot-Leclereq, M.-P.; Tulkens, P. M. Comparative stability studies of antipseudomonal β- lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motoroperated syringes (intensive care units). Antimicrob. Agents Chemother., 2002, 46, 2327-2332.
66. Karran, S. J.; Sutton, G.; Gartell, P.; Karran, S. E.; Finnis, D.; Blenkinsop, J. Imipenem prophylaxis in elective colorectal surgery. Br. J. Surg., 1993, 80, 1196-1198.
67. Miyadera, T.; Sugimura, Y.; Hashimoto, T.; Tanaka, T.; Iino, K.; Shibata, T.; Sugawara, S. Synthesis and in vitro activity of a new carbapenem, RS-533. J. Antibiot., 1983, 36, 1034-1039.
68. Shimada, J.; Kawahara, Y. Overview of a new carbapenem, panipenem/betamipron. Drugs Exp. Clin. Res., 1994, 20, 241-245.
69. Kozawa, O.; Uematsu, T. Pharmacokinetic and dynamic properties of carbapenem antibiotics. Recent Res. Dev. Antimicrob. Agents Chemother., 1999, 3, 441-451.
70. Mouton, J. W.; Touzw, D. J.; Horrevorts, A. M.; Vinks, A. A. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin. Pharmacokinet, 2000, 39, 185-201.
71. Ohashi, N.; Uematsu, T.; Nagashima, S.; Kanamaru, M.; Tajima, N.; Togawa, A.; Hishida, A. Pharmacokinetics of panipenem/ betamipron in patients with end-stage renal disease. J. Infect. Chemother., 2005, 11, 24-31.
72. Matsumoto, T.; Muratani, T. Newer carbapenems for urinary tract infections. Int. J. Antimicrob. Agents, 2004, 24, S35-S38.
73. Hirouchi, Y.; Naganuma, H.; Kawahara, Y.; Okada, R.; Kamiya, A.; Inui, K.; Hori, R. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn. J. Pharmacol., 1994, 66, 1-6.
74. Goa, K. L.; Noble, S. Panipenem/betamipron. Drugs, 2003, 63, 913-925.
75. Kwon, K.; Cheong, H. S.; Rhee, J. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. Jpn. J. Clin. Oncol., 2008, 38, 49-55.
76. Suzuki, K.; Horiba, M.; Naide, Y. Clinical study on panipenem/ betamipron in bacterial prostatitis. Chemotherapy, 1991, 39, 773-777.
77. Yamamoto, T.; Yasuda, J.; Iwasaku, K. Basic and clinical studies on panipenem/betamipron in obstetrics and gynecology. Chemotherapy, 1991, 39, 636-646.
78. Kurata, K. Investigation of panipenem/betamipron levels in sera and various tissues in patients of orthopedic surgery. Jpn. J. Antibiot., 1992, 45, 155-159.
79. Hara, K.; Hiraga, Y.; Omichi, M. A Comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia. Chemotherapy, 1992, 40, 509-531.
80. Kurihara, A.; Hisaoka, M.; Mikuni, N.; Kamoshida, K. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: correlation to concentration in central nervous system. J. Pharmacobiodyn, 1992, 15, 325-332.
81. Kumagai, T.; Matsunaga, H.; Machida, Y.; Nagase, Y.; Hikida, M.; Nagao, Y. Preparation of 2-heterocyclylthio-1-methylcarbapenem-3-carboxylates as antibacterial agents. Eur. Pat. Appl. EP., 289801, 1988.
82. Perry, C. M.; Ibbotson, T. Biapenem. Drugs, 2002, 62, 2221-2234.
83. Hikida, M.; Kawashima, K.; Yoshida, M. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J. Antimicrob. Chemother., 1992, 30, 129-134.
84. Kuwahara, K.; Yokota, T. A new carbapenem, biapenem, its in vitro activity, affinity to bacterial PBPs, and stability to human renal dehydropeptidase-I. Chemotherapy, (Tokyo) 1994, 42 (Suppl.4), 26-36.
85. ® (biapenem) prescribing information. Kanagawa, Japan: Meiji, 2002.
86. Nakashima, M.; Uematsu, T., Ueno, K. Phase I study of L-627, biapenem, a new parentral carbapenem antibiotic. Int. J. Clin. Pharmacol. Ther. Toxicol., 1993, 31, 70-76.
87. Koeppe, P.; Hoffler, D.; Fitzen, B. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. Arzneimittelforschung, 1997, 47, 1250-1256.
88. Liu, C.; Tu, Z.; Huang, W.; Yu, D.; Li, C.; Zheng, X. A Comparison of in vitro antibacterial activities of biapenem and imipenem against clinical isolates of respiratory and urinary tract infections. Zhonghua Jianyan Yixue Zazhi, 2007, 30, 770-773.
89. Alonso, R.; Fernandez-Aranguiz, A.; Colom, K.; Morla, A.; Suinaga, E.; Umaran, A.; Cisterna, R. In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae. Eur. J. Clin. Microbiol. Infect. Dis., 1994, 13, 820-822.
90. Chen, H. Y.; Livermore, D. M. Comparative in vitro activity of biapenem against enterobacteria with β-lactamase-mediated antibiotic resistance. J. Antimicrob. Chemother., 1994, 33, 453-464.
91. Hikara, Y.; Matsuda, J.; Mochida, C. Annual changes in susceptibility of clinical isolates to biapenem. Jpn. J. Chemother., 2002, 50, 329-351.
92. Ubukata, K.; Chiba, N.; Kobayashi, R. Comparison of in vitro activity of biapenem with other antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Chemother. Jpn, 2002, 50, 1-10.
93. Azami, H.; Barrett, D.; Tanaka, A.; Sasaki, H.; Matsuda, K.; Sakurai, M.; Terasawa, T.; Shirai, F.; Chiba, T.; Matsumoto, Y.; Tawara, S. Synthesis and antibacterial activity of novel 4-pyrrolidinylthio carbapenems. Part IV. 2-Alkyl substituents containing cationic heteroaromatics linked via a C-C bond. Bioorg. Med. Chem, 2001, 9, 961-982.
94. Matsumoto, F.; Inoue, M.; Sakurai, I. A Comparative study of biapenem and imipenem/cilastatin in lower respiratory infections. Jpn. J. Chemother., 2000, 48, 45-67.
95. Abe, T.; Isoda, T.; Sato, C.; Mihira, A.; Tamai, S.; Kumagai, T. Preparation of 2-[1-(1,3-thiazolin-2-ylazetidin-3-yl)thio]carbapenem derivatives. Eur. Pat. Appl. EP, 632039, 1995.
96. Muratani, T.; Doi, K.; Kobayashi, T.; Nakamura, T.; Matsumoto, T. Antimicrobial activity of tebipenem against various clinical isolates from various specimen, mainly urinary tract. Jpn. J. Antibiot., 2009, 62, 116-126.
97. Hikida, M.; Itahashi, K.; Igarashi, A.; Shiba, T.; Kitamura, M. In vitro antibacterial activity of LJC 11,036, an active metabolite of L- 084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Antimicrob. Agents Chemother., 1999, 43, 2010-2016.
98. Miyazaki, S.; Hosoyama, T.; Furuya, N.; Ishii, Y.; Matsumoto, T.; Ohno, A.; Tateda, K.; Yamaguchi, K. In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. Antimicrob. Agents Chemother., 2001, 45, 203-207.
99. Kobayashi, R.; Konomi, M.; Hasegawa, K.; Morozumi, M.; Sunakawa, K.; Ubukata, K. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob. Agents Chemother., 2005, 49, 889-894.
100. Yokokawa, M.; Yano, M.; Nakashima, M. L-084, a new oral carbapenem: pharmacokinetics and tolerance observed in the phase I studies. 39th Intersci. Conf. Antimicrob. Agents Chemother., 1999, Abstr. F388.
101. Tanaka, K.; Watanabe, K. In vitro tebipenem activity against anaerobic bacteria. Nippon Kagaku Ryoho Gakkai Zasshi, 2009, 57, 30-37.
102. Yamada, K.; Sugano, T.; Baba, N.; Takayama, Y.; Mikuniya, T.; Maebashi, K. In vitro antimicrobial activity of tebipenem. Nippon Kagaku Ryoho Gakkai Zasshi, 2009, 57, 1-14.
103. Sato, M.; Takemura, M.; Atarashi, S.; Higashi, K.; Nagahara, T.; Furukawa, M.; Ikeuchi, T.; Osada, Y. Modification of the cysteamine side chain of thienamycin. III. J. Antibiot., 1987, 40, 1292-1302.
104. Sumita, Y.; Fukasawa, M.; Okuda, T. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J. Antibiot., 1990, 43, 314-320.
105. Sunagawa, M.; Matsumura, H.; Inoue, T.; Fukasawa, M.; Kato, M. A Novel carbapenem antibiotic, SM-7338 Structure-activity relationships. J. Antibiot., 1990, 43, 519-532.
106. Oh, C.-H.; Cho, J.-H. Studies on the synthesis and antibacterial activity of new zwitterionic carbapenems. J. Antibiot., 1994, 47, 126-128.
107. Shin, K. J.; Koo, K. D.; Yoo, K. H.; Kim, D. C.; Kim, D. J.; Park, S. W. Synthesis and biological properties of new 1β- methylcarbapenems having tetrazolothioether moiety. Bioorg. Med. Chem. Lett., 2000, 10, 1421-1425.
108. Shin, K. J.; Koo, K. D.; Yoo, K. H.; Kang, Y. K.; Park, S. W.; Kim, D. J. Synthesis and biological properties of new 1β-methylcarbapenems containing heteroaromatic thioether moiety. Bioorg. Med. Chem. Lett., 2001, 11, 2397-2399.
109. Oh, C.-H.; Cho, H.-W.; Lee, I.-K.; Gong, J.-Y.; Choi, J.-H.; Cho, J.-H. Synthesis and antibacterial activity of 1β-methyl-2-(5- substituted thiazolidinopyrrolidin-3-ylthio)carbapenems and related compounds. Arch. Pharm. Pharm. Med. Chem., 2002, 4, 152-158.
110. Oh, C.-H.; Cho, H.-W.; Baek, D.; Cho, J.-H. Synthesis and antibacterial activity of 1β-methyl-2-(5-substituted thiazolo pyrrolidin-3- ylthio)carbapenem derivatives. Eur. J. Med. Chem., 2002, 37, 743-754.
111. Cho, H.-W.; Oh, C.-H.; Lee, J.-S.; Lee, S.-C.; Choi, J.-H.; Cho, J.-H. Synthesis and antibacterial activities of 4-pyrrolidinylthio carbapenems: containing heteroaromatics as a side chain. Arch. Pharm. Pharm. Med. Chem., 2003, 336, 495-503.
112. Oh, C.-H.; Lee, S.-C.; Cho, J.-H. Synthesis and antibacterial activity of 1β-methyl-2-[5-(N-substituted-2-hydroxy iminoethyl)pyrrolidin-3-ylthio]carbapenem derivatives. Eur. J. Med. Chem., 2003, 38, 751-758.
113. Oh, C.-H.; Lee, S.-C.; Cho, J.-H. Synthesis and biological activity of 1β-methyl-2-[5-(2-N-substituted aminoethylcarbamoyl)pyrrolidin-3-ylthio]carbapenem derivatives. Eur. J. Med. Chem., 2003, 38, 841-850.
114. Lee, J. H.; Lee, K. S.; Kang, Y. K.; Yoo, K. H.; Shin, K. J.; Kim, D. C.; Kong, J. Y.; Lee, Y.; Lee, S. J.; Kim, D. J. Synthesis and biological activity of novel 1β-methylcarbapenems with oxyiminopyrrolidinylamide moiety. Bioorg. Med. Chem. Lett., 2003, 13, 4399-4403.
115. Oh, C.-H.; Cho, J.-H. Synthesis and biological evaluation of 1β- methylcarbapenems having guanidine moieties. Eur. J. Med. Chem., 2006, 41, 50-55.
116. Han, T.; Cho, J.-H; Oh, C.-H. Synthesis and biological evaluation of 1β-methylcarbapenems having cyclic thiourea moieties and their related compounds. Eur. J. Med. Chem., 2006, 41, 825-832.
117. Jeon, H. C.; Kim, J.-W.; Hong, J. H.; Cho, J.-H.; Oh, C.-H. Synthesis and in vitro activity of a series of 1β-methylcarbapenem derivatives. Eur. J. Med. Chem., 2006, 41, 1201-1209.
118. Lee, K. S.; Lim, J. H.; Kang, Y. K.; Yoo, K. H.; Kim, D. C.; Shin, K. J.; Kim, D. J. Synthesis and antibacterial activities of new 1β- methylcarbapenems having aminopyrimidinylthioether moiety. Eur. J. Med. Chem., 2006, 41, 1347-1351.
119. Jeon, H.; Jo, N. H.; Yoo, K. H.; Choi, J.-H.; Cho, H.; Cho, J.-H.; Oh, C.-H. Synthesis and antibacterial evaluation of 1β-methyl-2-[5- (1-methoxyimino-2-substituted sulfonamideethyl) pyrrolidin-3- ylthio]carbapenems and their related compounds. Eur. J. Med. Chem., 2007, 42, 358-364.
120. Kim, S. J.; Park, H. B.; Lee, J. S.; Jo, N. H.; Yoo, K. H.; Baek, D.; Kang, B.-W.; Cho, J.-H.; Oh, C.-H. Novel 1β-methylcarbapenems having cyclic sulfonamide moieties: Synthesis and evaluation of in vitro antibacterial activity. Eur. J. Med. Chem., 2007, 42, 1176-1183.
121. Jung, M.-H.; Hong, J. H.; Cho, J.-H.; Oh, C.-H. Synthesis and in vitro activity of new 1β-methylcarbapenem derivatives as antibacterial agents. Arch. Pharm. Chem. Life Sci., 2008, 341, 780-786.
122. Fukasawa, M.; Sumita, Y.; Harabe, E. T.; Tanio, T.; Nouda, H.; Kohzuki, T.; Okuda, T.; Matsumura, H.; Sunagawa, M. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother., 1992, 36, 1577-1579.
123. Edwards, S. J.; Emmas, C. E.; Campbell, H. E. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr. Med. Res. Opin., 2005, 21, 785-794.
124. Edwards, J. R.; Turner, P. J.; Wannop, C.; Withnell, E. S.; Grindey, A. J.; Nairn, K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob. Agents Chemother., 1989, 33, 215-222.
125. Patzer, J. A.; Dzierzanowska, D.; Turner, P. J. Trends in antimicrobial susceptibility of Gram-negative isolates from a pediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). J. Antimicrob. Chemother., 2008, 62, 369-375.
126. Yamaguchi, K.; Ishii, Y.; Iwata, M.; Watanabe, N.; Uehara, N.; Yasujima, M.; Kasai, T.; Suwabe, A.; Yamahata, K.; Kaku, M.; Kanemitsu, K.; Imafuku, Y.; Nishiyama, K.; Murakami, M.; Yomoda, S.; Taniguchi, N.; Yamada, T.; Nomura, F.; Watanabe, M.; Kanno, H.; Aihara, M.; Maesaki, S.; Hashikita, G.; Kondo, S.; Misawa, S.; Horiuchi, H.; Tazawa, Y.; Nakashima, H.; Takemura, H.; Okada, M.; Yamazaki, F.; Horii, T.; Maekawa, M.; Baba, H.; Ishigo, S.; Fujita, N.; Komori, T.; Ichiyama, S.; Iinuma, Y.; Maeda, S.; Yamanaka, K.; Murata, Y.; Matsuo, S.; Kohno, H.; Kinoshita, S.; Fujita, J.; Negayama, K.; Murase, M.; Miyamoto, H.; Kusano, N.; Mihara, E.; Itaha, H.; Ono, J.; Yoshimura, H.; Yanagihara, K.; Matsuda, J.; Saikawa, T.; Hiramatsu, K. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn. J. Antibiot., 2007, 60, 344-377.
127. Dagan, R.; Velghe, L.; Rodda, J. L.; Klugman, K. P. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J. Antimicrob. Chemother., 1994, 34, 175-179.
128. Nicasio, A. M.; Quintiliani, R. Jr.; De Ryke, C. A.; Kuti, J. L.; Nicolau, D. P. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem. Ann. Pharmacother., 2007, 41, 1077-1081.
129. Byl, B.; Jacobs, F.; Roucloux, I.; De Franquen, P.; Cappello, M.; Thys, J.-P. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob. Agents Chemother., 1999, 43, 681-682.
130. Gill, C. J.; Jackson, J. J.; Gerckens, L. S.; Pelak, B. A.; Thompson, R. K.; Sundelof, J. G.; Kropp, H.; Rosen, H. In vivo avtivity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob. Agents Chemother., 1998, 42, 1996-2001.
131. Keating, G. M.; Perry, C. M. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs, 2005, 65, 2151-2178.
132. Fuchs, P. C.; Barry, A. L.; Brown, S. D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob. Agents Chemother., 2001, 45, 1915-1918.
133. Moczygemba, L. R.; Frei, C. R.; Burgess, D. S. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin. Ther., 2004, 26, 1800-1807.
134. Jones, R. N.; Sader, H. S.; Fritsche, T. R. Comparative activity of doripenem and three other carbapenems tested against Gramnegative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis., 2005, 52, 71-74.
135. Boselli, E.; Breilh, D.; Djabarouti, S.; Bel, J. C.; Saux, M. C.; Allaouchiche, B. Diffusion of ertapenem into bone and synovial tissues. J. Antimicrob. Chemother., 2007, 60, 893-896.
136. DiNubile, M. J.; Lipsky, B. A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J. Antimicrob. Chemother., 2004, 53(Suppl. S2), ii37-ii50.
137. Itani, K. M.; Wilson, S. E.; Awad, S. S.; Jensen, E. H.; Finn, T. S.; Abramson, M. A. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N. Eng. J. Med., 2006, 355, 2640-2651.
138. Yellin, A. E.; Hassett, J. M.; Fernandez, A.; Geib, J.; Adeyi, B.; Woods, G. L.; Teppler, H. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int. J. Antimicrob. Agents, 2002, 20, 165-173.
139. Solomkin, J.; Teppler, H.; Graham, D. R.; Gesser, R. M.; Meibohm, A. R.; Roy, S.; Woods, G. L. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. J. Antimicrob. Chemother., 2004, 53(Suppl. S2), ii51-ii57.
140. Navarro, N. S. Jr; Campos, M. I.; Alvarado, R.; Quintero, N.; Branicki, F. J.; Wei, J.; Shivaprakash, M.; Vrijens, F.; Giezek, H.; Chan, C. Y.; DiNubile, M. J. Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. Int. J. Surg., 2005, 3, 25-34.
141. Dela Pena, A. S.; Asperger, W.; Kockerling, F.; Raz, R.; Kafka, R.; Warren, B.; Shivaprakash, M.; Vrijens, F.; Giezek, H.; DiNubile, M. J.; Chan, C. Y. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J. Gastrointest. Surg., 2006, 10, 567-574.
142. Iso, Y.; Irie, T.; Nishino, Y.; Motokawa, K.; Nishitani, Y. A Novel 1β-methylcarbapenem antibiotic, S-4661. Synthesis and structureactivity relationships of 2-(5-substituted pyrrolidin-3-ylthio)- 1β-methylcarbapenems. J. Antibiot., 1996, 49, 199-209.
143. Lister, P. D. Carbapenems in the USA: focus on doripenem. Expert Rev. Anti-Infect. Ther., 2007, 5, 793-809.
144. Keam, S. J. Doripenem: a review of its use in the treatment of bacterial infections. Drugs, 2008, 68, 2021-2057.
145. Shan, P. M. Parentral carbapenems. Clin. Microbiol. Infect., 2008, 14 (Suppl. 1), 175-180.
146. Mori, M.; Hikida, M.; Nishihara, T.; Nasu, T.; Mitsuhashi, S.; Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J. Antimicrob. Chemother., 1996, 37, 1034-1036.
147. Jones, R. N.; Huynh, H. K.; Biedenbach, D. J.; Fritsche, T. R.; Sader, H. S.; Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother., 2004, 54, 144-154.
148. Fritsche, T. R.; Stilwell, M. G.; Jones, R. N. Antimicrobial activity of doripenem (S-4661): a global surveillance report. Clin. Microbiol. Infect., 2005, 11, 974-984.
149. Tsuji, M.; Ishii, Y.; Ohno, A.; Miyazaki, S.; Yamaguchi, K. In vitro and in vivo antibacterial activity of S-4661, a new carbapenem. Antimicrob. Agents Chemother., 1998, 42, 94-99.
150. Watanabe, A.; Takahashi, H.; Kikuchi, T.; Kobayashi, T.; Gomi, K.; Fujimura, S.; Tokue,Y.; Nukiwa, T. Comparative in vitro activity of S-4661, a new parentral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy, 2000, 46, 184-187.
151. Nomura, S.; Nagayama, A. In vitro antibacterial activity of S-4661, a new parentral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J. Chemother., 2002, 14, 155-160.
152. Goldstein, E. J.; Citron, D. M.; Merriam, C. V.; Warren, Y. A.; Tyrrell, K. L.; Fernandez, H. T. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob. Agents Chemother., 2008, 52, 761-766.
153. Chen, Y.; Garber, E.; Zhao, Q.; Ge, Y.; Wikler, M. A.; Kaniga, K.; Saiman, L. In vitro activity of doripenem (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother., 2005, 49, 2510-2511.
154. Traczewski, M. M.; Brown, S. D. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob. Agents Chemother., 2006, 50, 819-821.
155. Chastre, J.; Wunderink, R.; Prokocimer, P.; Lee, M.; Kaniga, K.; Friedland, I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med., 2008, 36, 1089-1096.
156. Lucàsti, C.; Jasovich, A.; Umeh, O.; Jiang, J.; Kaniga, K.; Friedland, I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin. Ther., 2008, 30, 868-883.
157. Merchant, S.; Gast, C.; Nathwani, D.; Lee, M.; Quintana, A.; Ketter, N.; Friedland, I.; Ingham, M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilatorassociated pneumonia. Clin. Ther., 2008, 30, 717-733.
158. Rea-Neto, A.; Niederman, M.; Lobo, S. M.; Schroeder, E.; Lee, M.; Kaniga, K.; Ketter, N.; Prokocimer, P.; Friedland, I. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr. Med. Res. Opin., 2008, 24, 2113-2126.
159. Doribax Package Insert (2008) Doribax. Raritan, N. J.: Ortho-McNeil Pharmaceutical, Inc. Available at http://www.doribax.com/doribax/shared/pi/doribax.pdf
160. Pillar, C. M.; Torres, M. K.; Brown, N. P.; Shah, D.; Sahm, D. F. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob. Agents Chemother., 2008, 52, 4388-4399.
161. Poulakou, G.; Giamarellou, H. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gramnegative pathogens. Exp. Opin. Investig. Drugs, 2008, 17, 749-771.
162. Kim, A.; Banevicius, M. A.; Nicolau, D. P. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother., 2008, 52, 2497-2502.
163. Mendes, R. E.; Rhomberg, P. R.; Bell, J. M.; Turnidge, J. D.; Sader, H. S. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extendedspectrum agents. Diagn. Microbiol. Infect. Dis., 2009, 63, 415-425.
164. Dedhia, H. V.; McKnight, R. Doripenem: position in clinical practice. Exp. Rev. Anti-Infect. Ther., 2009, 7, 507-514.
165. The medical letter, Doripenem (Doribax)-a new parentral carbapenem. Med. Lett. Drugs Ther., 2008, 50, 5-7.
166. Kobayashi, Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J. Infect. Chemother., 2005, 11, 259-261.
167. Jones, R. N.; Bell, J. M.; Sader, H. S.; Turnidge, J. D.; Stilwell, M. G. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagn. Microbiol. Infect. Dis., 2009, 63, 434-439.
168. Maruyama, T.; Yamamoto, Y.; Kano, Y.; Kurazono, M.; Matsuhisa, E.; Takata, H.; Takata, T.; Atsumi, K.; Iwamatsu, K.; Shitara, E. CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity. Bioorg. Med. Chem., 2007, 15, 6379-6387.
169. Thye, D. A.; Kilfoilm, T.; Leighton, A. Doripenem: a phase I study to evaluate safety, tolerability and pharmacokinetics in a Western healthy volunteer population. 43rd Intersci. Conf. Antimicrob. Agents Chemother., 2003, PA-21.
170. Doripenem: S 4661. Drugs in R&D 2003, 4, 363-365.
171. Nakagawa, S.; Kato, S.; Murase, S.; Okamoto, O.; Mitomo, R.; Yamamoto, K.; Yamada, K.; Fukatsu, H. Aminoalkylpyrrolidinylthiocarbapenem derivatives. Eur. Pat. Appl. EP, 545290, 1993.
172. Ohtake, N.; Okamoto, O.; Mitomo, R.; Kato, Y.; Yamamoto, K.; Haga, Y.; Fukatsu, H.; Nakagawa, S. 1β-Methyl-2-(5-substituted pyrrolidin-3-ylthio)carbapenems; 3. Synthesis and antibacterial activity of BO-2727 and its related compounds. J. Antibiot., 1997, 50, 598-613.
173. Nakagawa, S.; Hashizume, T.; Matsuda, K.; Sanada, M.; Okamoto, O.; Fukatsu, H.; Nakata, N. In vitro activity of a new carbapenem antibiotic, BO-2727, with a potent antipseudomonal activity. Antimicrob. Agents Chemother., 1993, 37, 2756-2759.
174. Asahi, Y.; Miyazaki, S.; Ymaguchi, K. In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem. Antimicrob. Agents Chemother., 1995, 39, 1030-1037.
175. Kawamoto, I.; Shimoji, Y.; Kanno, O.; Kojima, K.; Ishikawa, K.; Matsuyama, E.; Ashida, Y.; Shibayama, T.; Fukuoka, T.; Ohya, S. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J. Antibiot., 2003, 56, 565-579.
176. Thomson, K. S.; Moland, E. S. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant Staphylococci and Pseudomonas aeruginosa. J. Antimicrob. Chemother., 2004, 54, 557-562.
177. Koga, T.; Abe, T.; Inoue, H.; Takenouchi, T.; Kitayama, A.; Yoshida, T.; Masuda, N.; Sugihara, C.; Kahuta, M.; Nakagawa, M.; Shibayama, T.; Matsushita, Y.; Hirota, T.; Ohya, S.; Utsui, Y.; Fukuoka, t.; Kuwahara, S. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parentral carbapenem. Antimicrob. Agents Chemother., 2005, 49, 3239-3250.
178. Jones, M. E.; Brown, N. P.; Dannemann, B.; Sahm, D. F. Bactericidal activity of RO4908463 against beta-lactam-susceptible and resistant target species. 46th Intersci. Conf. Antimicrob. Agents Chemother. 2006, Abstr. E-0227.
179. Morinaga, Y.; Yanagihara, K.; Nakamura, S.; Yamamoto, K.; Izumikawa, K.; Seki, M.; Kakeya, H.; Yamamoto, Y.; Yamada, Y.; Kohno, S.; Kamihira, S., In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in murine chronic respiratory tract infection model. J. Antimicrob. Chemother., 2008, 62, 1326-1331.
180. Tanaka, K.; Mikamo, H.; Nakao, K.; Ichiishi, T.; Goto, T.; Yamagishi, Y.; Watanabe, K. In vitro activity of tomopenem (CS- 023/RO4908463) against anaerobic bacteria. Antimicrob. Agents Chemother., 2009, 53, 319-322.
181. Koga, T.; Masuda, N.; Kakuta, M.; Namba, E.; Sugihara, C.; Fukuoka, T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2008, 52, 2849-2854.
182. Sugihara, K.; Matsushita, Y.; Yamamura, N.; Uemori, M.; Sugihara, C.; Tokumitsu, A.; Inoue, H.; Kakuta, M.; Namba, E.; Nasu, H.; Koga, T. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and MRSA in murine thigh infection model. 48th Intersci. Conf. Antimicrob. Agents Chemother. 2008, Abstr. A-027.
183. Jones, M. E.; Brown, N. P.; Dannemann, B.; Sahm, D. F. RO4908463 demonstrates a low potential for in vitro selection of resistance in S. aureus, S. pneumoniae, E. coli, E. cloacae, K. pneumoniae, and P. aeruginosae. 46th Intersci. Conf. Antimicrob. Agents Chemother. 2006, Abstr. C1-0035.
184. Shibayama, T.; Sugiyama, D.; Kamiyama, E.; Tokui, T.; Hirota, T.; Ikeda, T. Characterization of CS-023 (RO4908463), a novel parentral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab. Pharmacokinet, 2007, 22, 41-47.
185. Shibayama, T.; Matsushita, Y.; Hirota, T.; Ikeda, T.; Kuwahara, S. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male caucasian volunteers. Antimicrob. Agents Chemother., 2006, 50, 4186-4188.